Can tumor lysis syndrome cause leukocytosis?

Tumor Lysis Syndrome Does Not Cause Leukocytosis

Tumor lysis syndrome (TLS) is characterized by metabolic derangements from rapid cell breakdown—specifically hyperuricemia, hyperkalemia, hyperphosphatemia, and hypocalcemia—but leukocytosis is not a consequence of TLS; rather, leukocytosis (particularly hyperleukocytosis) is a pre-existing condition that predisposes patients to developing TLS. 1

Understanding the Relationship

The confusion likely stems from the fact that these two conditions frequently coexist in hematologic malignancies, but the causal relationship is the opposite of what the question suggests:

Leukocytosis as a Risk Factor for TLS

• Hyperleukocytosis (WBC >100,000/mm³) is a well-established risk factor for developing TLS, not a result of it 2, 3
• The higher the white blood cell count, the greater the risk: TLS develops in 26% of patients with WBC <100,000/mm³, 50% with WBC 100,000-200,000/mm³, and up to 100% with WBC >300,000/mm³ 3
• Multiple case reports demonstrate patients presenting with both hyperleukocytosis and TLS simultaneously, where the elevated WBC count preceded and contributed to TLS development 4, 5, 6

What TLS Actually Causes

According to established guidelines, TLS results from the massive release of intracellular contents into the bloodstream following rapid tumor cell lysis 1. The defining laboratory abnormalities are:

• Hyperuricemia (from nucleic acid breakdown)
• Hyperkalemia (from intracellular potassium release)
• Hyperphosphatemia (from intracellular phosphate release)
• Hypocalcemia (secondary to hyperphosphatemia)
• Acute kidney injury (from uric acid and calcium phosphate precipitation)

Clinical Pitfall to Avoid

Do not mistake the pre-existing leukocytosis in acute leukemias or lymphomas as being caused by TLS. The elevated white blood cell count represents the underlying malignancy itself. When you see a patient with both hyperleukocytosis and TLS, recognize that:

1. The leukocytosis is from the hematologic malignancy (ALL, AML, Burkitt's lymphoma, CML blast crisis)
2. The high tumor burden from hyperleukocytosis creates risk for TLS
3. TLS develops when these cells lyse (spontaneously or after chemotherapy initiation)

Monitoring Implications

In patients with hyperleukocytosis at risk for TLS, guidelines recommend monitoring 7:

• Every 12 hours for first 3 days: LDH, uric acid, sodium, potassium, creatinine, BUN, phosphorus, calcium
• Every 6 hours if TLS develops: vital signs, urine output, electrolytes, renal function

The leukocyte count itself is monitored to assess disease burden and response to therapy, not because TLS would elevate it.